National Academies Press: OpenBook
« Previous: II. Issues in Biotechnology and Information Technology
Suggested Citation:"III. Findings and Recommendations." National Research Council. 2001. Capitalizing on New Needs and New Opportunities: Government-Industry Partnerships in Biotechnology and Information Technologies. Washington, DC: The National Academies Press. doi: 10.17226/10281.
×

III
FINDINGS AND RECOMMENDATIONS

Suggested Citation:"III. Findings and Recommendations." National Research Council. 2001. Capitalizing on New Needs and New Opportunities: Government-Industry Partnerships in Biotechnology and Information Technologies. Washington, DC: The National Academies Press. doi: 10.17226/10281.
×
This page in the original is blank.
Suggested Citation:"III. Findings and Recommendations." National Research Council. 2001. Capitalizing on New Needs and New Opportunities: Government-Industry Partnerships in Biotechnology and Information Technologies. Washington, DC: The National Academies Press. doi: 10.17226/10281.
×

Summary of Findings

I. Information Technology and Biotechnology are Key Sectors for the 21stCentury. The information and biotechnology sectors are each very important to America's economy, security, and well-being.1 Although some expect the 21st century to be dominated by the Biotechnology Revolution, the Information Revolution begun in the 20th century has not run its course. Advances in information technologies remain central to economic growth; they will also be critical to progress in the Biotechnology Revolution itself. Reaping the health benefits of sequencing the human genome depends on processing and making sense of enormous amounts of data that, in turn, will be made possible by advances in computing and networking technologies. At the same time, information technology will advance based on a better understanding and use of the principles of biological systems and mechanisms. Already, NASA has developed flight control software for the F-15 aircraft based on neural network principles.2 Biological models also may

1  

As William Spencer points out in his Introduction to the proceedings, a substantial portion of the $225 billion in private and public R&D spending in 1998 were in the fields of biotechnology and computing.

2  

This software requires 10,000 lines of code instead of the million lines required by traditional flight control software. The aircraft performed better in test flights, because the neural network program was more responsive to changes (such as loss of aircraft control surfaces) and adapted itself to correct related software faults. See Daniel S.Goldin, “The Cornucopia of the Future” in this volume.

Suggested Citation:"III. Findings and Recommendations." National Research Council. 2001. Capitalizing on New Needs and New Opportunities: Government-Industry Partnerships in Biotechnology and Information Technologies. Washington, DC: The National Academies Press. doi: 10.17226/10281.
×

lead to improved computer hardware architecture and other technologies, such as MEMS and nanotechnology.3

II. Multidisciplinary Approaches Are Increasingly Needed in Science and Engineering Research. More and more, progress in research depends on multidisciplinary efforts.4 Complex research problems require the integration of both people and new knowledge across a range of disciplines. In turn, this requires knowledge workers with interdisciplinary training in mathematics, computer science, and biology. Bioinformatics is a key example of a highly multidisciplinary field requiring workers with interdisciplinary training.5

Biotechnology R&D and information technology R&D each provide tools and models useful for the other. Interdependencies also exist among chemistry, physics, and structural biology, and among mathematics, computer engineering, and genomics. Further examples of these interdependencies can be found in the complementary roles of the physical sciences and engineering in nano-scale semiconductor work, and in the overall important role engineering research plays in providing new research tools and diagnostics in all of these areas.6

III. Government-Industry and University-Industry Partnerships Have Often Been Effective in Supporting the Development of New Technologies. Symposium participants noted many examples of partnerships involving the federal government, universities, and industry that have contributed to the development and strengthening of leading U.S. industries.7 Mechanisms to

3  

Jane Alexander, “Biofutures for Multiple Missions” in this volume, gives a number of examples of microsystems based on biological models.

4  

See the presentations of Edward Penhoet, William Bonvillian, Marvin Cassman, and Rita Colwell in the Proceedings. These participants note that biotechnology research is expected to become increasingly multidisciplinary but must overcome particular constraints if biotechnology is to reach its full capacity and usher a rapid advance in knowledge.

5  

See Paula E.Stephan and Grant Black, “Bioinformatics: Emerging Opportunities and Emerging Gaps,” in this volume. The authors find that the field of bioinformatics is highly multidisciplinary, requiring a combination of understanding and skills in mathematics, computer science, and biology. Their paper explores constraints to more robust multidisciplinary research in this important area.

6  

See the presentations of Daniel Goldin, Al Romig, Paul Horn, and Mark Boguski, in the Proceedings section, on the future technologies that require current investments in multidisciplinary research.

7  

For a description of the importance of the federal partnership with U.S. industry in the development of the computer, see the paper by Kenneth Flamm in this volume. He notes that “In the first decade after the war, most significant computer research and development projects in the United States depended—directly or indirectly—on funding from the United States government, mainly from the U.S. military. The second decade of the computer, from the mid-1950s through the mid-1960s, saw rapid growth in commercial applications and utilization of computers. By the mid-1960s, business applications accounted for a vastly larger share of computer use. However, the government

Suggested Citation:"III. Findings and Recommendations." National Research Council. 2001. Capitalizing on New Needs and New Opportunities: Government-Industry Partnerships in Biotechnology and Information Technologies. Washington, DC: The National Academies Press. doi: 10.17226/10281.
×

support partnerships include the Engineering Research Centers and Science and Technology Centers funded by the NSF, NIST’s Advanced Technology Program, and the DOD’s former Technology Reinvestment Program. They also included activities funded by Cooperative Research and Development Agreements (CRADAs).8 SEMATECH, initially funded by government as well as industry, has played a key role in improving manufacturing technologies for the U.S. semiconductor industry.9

A Multidisciplinary Approach: Partnerships between universities and companies that cut across disciplines, though often challenging, are increasingly important to progress as biotechnology and information technologies become dependent on contributions from other fields. While projects led by individual investigators remain vital to general scientific and engineering advancement, solving complex problems in new areas such as bioinformatics and next-generation computing requires larger, multidisciplinary collaborations among scientists and engineering researchers. Both government agencies and industry groups can help overcome these institutional problems by funding multidisciplinary research projects focused on important complex problems.

Federal laboratories also offer important capabilities and institutional lessons for dealing with complex research problems. Historically, NIH has not directly supported industry R&D, but this is changing. In 1998, NIH laboratories entered into 166 CRADAs, and in 1999 NIH’s Small Business Inno-

   

continued to dominate the market for high-performance computers, and government-funded technology projects pushed much of the continuing advance at the frontiers of information technology over this period.

From the mid-1960s through the mid-1970s, continued growth in commercial applications of vastly cheaper computing power exploded. By the middle of the decade of the seventies, the commercial market had become the dominant force driving the technological development of the U.S. computer industry. The government role, increasingly, was focused on the very high-end, most advanced computers, in funding basic research, and in bankrolling long-term/leading-edge technology projects.” For a broader view, see Roger Noll and Linda Cohen, The Technology Pork Barrel, Washington, D.C.: The Brookings Institution, 1991. The authors observe that there are frequent failures as well as successes among federal R&D programs. They count among the successes telegraphy, hybrid seeds, aircraft, radio, radar, computers, semiconductors, and communications satellites. In short, much of the foundation for the modern economy. Noll and Cohen, op. cit. p. 3.

In this volume, see the presentations by Dale Jorgenson, Gordon Moore, and Kenneth Flamm in the Proceedings. In his overview of the semiconductor industry, Gordon Moore notes that government support has been effective in developing technologies—particularly those related to high-end semiconductor devices—that would not likely have otherwise emerged. In describing the role of SEMATECH, he also notes that federal support has strengthened the competitive position of the United States. See also the Preface to this report.

8  

See, for example, the presentation by Paul Horn, “Meeting the Needs: Realizing the Opportunities” in this volume.

9  

Gordon Moore, “The View from the Semiconductor Industry” in this volume.

Suggested Citation:"III. Findings and Recommendations." National Research Council. 2001. Capitalizing on New Needs and New Opportunities: Government-Industry Partnerships in Biotechnology and Information Technologies. Washington, DC: The National Academies Press. doi: 10.17226/10281.
×

vation Research Program awarded more than $300 million to small companies.10 This is expected to rise to $410 million in 2001.11

The availability of genome sequences has also prompted research on a new scale, leading to new types of partnerships in the biotechnology, pharmaceutical, and biomedical areas. Understanding the functioning of cells at the system level, or how thousands of genes and proteins interact, requires collaborations among large numbers of researchers with interdisciplinary backgrounds, including those with sophisticated computer skills.

Multidisciplinary research, with teams from different departments and organizations is needed to attack issues at the periphery of standard disciplinary boundaries.12 The advent of such organizations as the SNP Consortium, the Alliance for Cellular Signaling, and the Mouse Sequence Consortium—not to mention the organizational effort mounted to sequence the genome itself—illustrate the need for and possibilities of partnerships in biomedicine.13

IV. Federal R&D Funding and Other Innovation Policies Have Been Important in Supporting the Development of U.S. Industrial Capabilities in Computing and Biotechnology. The history of the U.S. biotechnology and computing sectors illustrates the value of sustained federal support, although federal roles and contributions have been different in the two areas:

  1. Computing and Semiconductors. In computing and semiconductors, the federal government has played four important roles since World War II.14

  • Antitrust. Antitrust policy played an important role in the creation of the semiconductor industry by requiring the pre-1984 AT&T to license broadly its patents in transistors.15

10  

Leon Rosenberg, “Partnerships in the Biotechnology Enterprise” in this volume, discusses the extent and importance of university-industry partnerships in the biomedical field. Some recent press reports put the amount substantially higher.

11  

Substantial funds are available to non-profit research centers, some to clinics associated with private firms. For increasing relationships between nonprofit research institutions and for-profit firms, see Chris Adams, “Laboratory Hybrids: How Adroit Scientists Aid Biotech Companies with Taxpayer Money—NIH Grants Go to Non-profits Tied to For-profit Firms set up by Researchers,” Wall Street Journal, New York: Dow Jones and Company, January 30, 2001.

12  

See Editorial, “Post-Genomic Cultures,” Nature, February 1, 2001, p. 545.

13  

These organizations are described in “Issues in Biotechnology and Information Technology,” in this volume.

14  

See the presentation by Gordon Moore in the Proceedings section for a nuanced view of the federal role in the development of the semiconductor industry.

15  

Moore, op. cit.

Suggested Citation:"III. Findings and Recommendations." National Research Council. 2001. Capitalizing on New Needs and New Opportunities: Government-Industry Partnerships in Biotechnology and Information Technologies. Washington, DC: The National Academies Press. doi: 10.17226/10281.
×
  • Procurement. Government procurement in the early days of both semiconductors and computers presented a valuable stimulus to technological development and industry growth; in addition to providing generous contracts, the government served as a reliable first customer, providing companies with early markets.16

  • R&D Funding. Federally funded R&D was important in developing certain niche areas (e.g., gallium-arsenide chips) and certain new areas of computing (e.g., ARPANET and 3D graphics). Reflecting the semiconductor industry’s dependence on research and its special needs, the federal research effort has been complemented by private support, such as the industry-created Semiconductor Research Corporation,17 and later through the SEMATECH Consortium—the highly regarded federal-industry partnership.18

  • High Performance Computing. The government has long played, and continues to play, an essential role in high-performance computing. There is usually only a small commercial market for the most powerful supercomputers; the government itself continues to act as the main purchaser of leading-edge machines for a variety of national missions. As a result, federal R&D support and procurement remain critical to progress in this field.19

  1. Biotechnology. It is widely recognized that federally funded research has played a central role in the development of the biotechnology industry. The federal government funds 90 percent of university-based health research in the United States.20 Many of the key discoveries and techniques of

16  

Kenneth Flamm, “Partnerships in the Computer Industry” in this volume. See also Kenneth Flamm, Targeting the Computer. Washington, DC: The Brookings Institution, 1987. p. 107. See also Martin Kenney, ed., Understanding Silicon Valley: The Anatomy of an Entrepreneurial Region, Stanford, CA: Stanford University Press, 2000.

17  

Moore, op. cit.

18  

See P.Grindley, D.C.Mowery, and B.S.Silverman, “The Design of High-Technology Consortia: Lessons from SEMATECH,” In Technological Infrastructure Policy: An International Perspective, M.Teubal, editor, Dordrecht: Kluwer Academic Publishing, 1996. Also see John Horrigan, “Cooperating Competitors: A Comparison of MCC and SEMATECH,” Monograph, Washington, D.C.: National Research Council, 1997. Also see National Research Council, Conflict and Cooperation in National Competition for High-Technology Industry, Washington, D.C.: National Academy Press, 1996, Supplement B, p. 141.

19  

National Research Council, Funding a Revolution: Government Support for Computing Research. Washington, D.C.: National Academy Press, 1999.

20  

Rosenberg, op. cit.

Suggested Citation:"III. Findings and Recommendations." National Research Council. 2001. Capitalizing on New Needs and New Opportunities: Government-Industry Partnerships in Biotechnology and Information Technologies. Washington, DC: The National Academies Press. doi: 10.17226/10281.
×

modern biotechnology have come out of university research funded by the National Institutes of Health (NIH). While the NIH continues to play a crucial role, corporate research also broadens the technology base. Indeed, other non-biological technologies, such as computing, have become increasingly important to the continued progress of the biotechnology industry.21

  1. Patent Policies. Federal patent policy also has a significant impact on these fields. Covering, as it does, areas as diverse as biotechnology and e-commerce, current federal patent policy is sometimes a source of uncertainty and, thus, could prove to be an obstacle to innovation.22 The federal government could help further stimulate innovation by clarifying patent rules (e.g., regarding biotechnology research tools) to reduce risks of litigation over patent issues.23

V. Limitations of Venture Capital. The U.S. venture capital market—the largest and best developed in the world—often plays a crucial role in the formation of new high-technology companies. Even so, the nature of the role and constraints posed by venture capital markets need to be better understood. The provision of venture capital, with its informed assessment and management oversight, is but one element of a larger innovation system. It is not a substitute for government support of long-term scientific and technological research. Indeed, the venture capital industry is not designed to support early-phase research and rarely does so. Venture capitalists do provide vital support to business efforts that show the potential of exploiting new technologies and business ideas.24 As such, venture funding tends to

21  

See the presentation by Mark Boguski on “Computing and the Human Genome” in this volume. See also the presentation of Jeffrey Schloss in National Research Council, The Advanced Technology Program: Challenges and Opportunities, Charles W.Wessner, editor, Washington, D.C.: National Academy Press, 1999, pp. 56–59. To hasten the development of computational tools in biotechnology, the NIH established the Biomedical Information Science and Technology Initiative in April 2000. The initiative “is aimed at making optimal use of science and technology to address problems in biology and medicine.” More information on the initiative is available at the NIH Web site: http://grants.nih.gov/grants/bistic/bistic2.cfm.

22  

The STEP Board is currently conducting a study on these and related issues led by Richard Levin, President of Yale University, and Mark Myers, Senior Vice President (retired) of Xerox, now with the Wharton School. A major conference was organized to explore this topic in February 2000. A report on the meeting, entitled Intellectual Property Rights in a Knowledge-Based Economy, is presently undergoing review. See also the National Research Council Web site on this topic: www.nationalacademies.org/ipr.

23  

Robert Blackburn, “Intellectual Property and Biotechnology” in this volume.

24  

See the statement by David Morgenthaler, past president of the National Venture Capital Association, in Panel I of the Proceedings of National Research Council, The Advanced Technology Program: Assessing Outcomes, Washington, D.C.: National Academy Press, 2001. Morgenthaler notes that “[the ATP] is an excellent program for developing enabling, or platform, technologies,

Suggested Citation:"III. Findings and Recommendations." National Research Council. 2001. Capitalizing on New Needs and New Opportunities: Government-Industry Partnerships in Biotechnology and Information Technologies. Washington, DC: The National Academies Press. doi: 10.17226/10281.
×

be concentrated, rather than evenly spread out across different sectors.25 As a result, areas with recognized long-term potential such as biotechnology may experience periods of very low venture capital funding. In part, this may be because they do not offer the returns perceived by investors in other areas such as information technologies and new Internet businesses. Consider, for example, that in 1999, U.S. venture capitalists invested approximately $59.5 billion, up from $4.9 billion in 1993.26 However, eighty percent of venture capital in 1999 was concentrated on Internet and related businesses, with perhaps $1.2 billion invested in biotechnology companies.27 Government support—through funding for promising technologies with less-assured returns—can partly compensate for this concentration.

VI. Biotechnology and Information Technology Present New Technological Challenges and Opportunities. There are a number of research areas in the two fields in which federal R&D funding could be very valuable. These include:

  1. Lithography. The semiconductor industry needs new lithography technologies. Within a few years, the size of features on chips will become so small that traditional optical lithography will no longer work. The Department of Energy and the national laboratories have conducted research on extreme ultraviolet (EUV) lithography. Funded originally for defense purposes, this research is having valuable spillover applications in the semiconductor industry. To capture this potential, a government-industry partnership, in the form of a CRADA led by Intel, is collaborating with DOE researchers to advance this technology.28

   

which can have broad applications but are long-term risky investments. Venture capitalists are not going to fund these opportunities, because they feel that they are at too early a stage of maturity. Governments can and should fund these technologies. In fact, it should do more than it is doing” (p. 67). Kenneth Flamm makes the same point in his presentation.

25  

Joshua Lerner discusses this “herding tendency” in the venture capital industry. See National Research Council, The Advanced Technology Program, Challenges and Opportunities, Washington, D.C.: National Academy Press, 1999, Introduction et passim. For a broader analysis of the venture capital industry, see Paul Gompers and Joshua Lerner, The Venture Capital Cycle. Cambridge, MA: The MIT Press, 2000. For a discussion of the requirements of early stage financing—in particular institutional requirements—and the limitations of the venture capital industry in this regard, see Lewis M.Branscomb and Philip E.Auerswald, Taking Technical Risks, Cambridge, MA: The MIT Press, 2001, Chapter 5.

26  

See the Web site of the National Venture Capital Association, www.nvca.org.

27  

Ibid.

28  

See David Mowery, Rosemarie Ziedonis, and Greg Linden, “National Technology Policy in Global Markets,” in Innovation Policy in the Knowledge-Based Economy, Maryann P.Feldman and Albert N.Link, eds., Boston, Dordrecht and London: Kluwer Academic Publishers, 2001.

Suggested Citation:"III. Findings and Recommendations." National Research Council. 2001. Capitalizing on New Needs and New Opportunities: Government-Industry Partnerships in Biotechnology and Information Technologies. Washington, DC: The National Academies Press. doi: 10.17226/10281.
×
  1. High Performance Computing. The future in high performance computing may belong to machines that are based on standard microprocessors rather than expensive specialty chips and architectures. However, harnessing the computing power of large numbers of microprocessors creates special technical problems. Federal support at DOE and NASA is proving valuable in addressing these issues.29

  2. Genomics. The genomics revolution has created a pressing need for improvements in computational biology/bioinformatics. Progress in this new field will depend, in turn, on the ability of universities and others to build and fund multidisciplinary research teams. Yet, the current university environment does little to encourage such teamwork. Along with research needs in bioinformatics, there is also a great need to train people with skills in both biology and computing. In addition to the computing aspects of bioinformatics, important opportunities exist in combining biology and semiconductors into so-called “gene chips,” or DNA analysis chips.

  3. Interdisciplinary Instruction and Multidisciplinary Research. Increasingly, the domains of both biotechnology and computing cover more than one disciplinary field. Given this fact, federal policies that encourage research collaboration within universities and among universities, federal laboratories, and companies may be particularly helpful in promoting future U.S. innovation.

VII. The Allocation of Federal Funding among Fields of Research Has Shifted Sharply in the Last Decade. In recent years, federal research funding has increased substantially for a few important and promising fields—e.g., biomedicine and computer science—while it has decreased in real terms for research in the physical sciences and much of engineering. Biomedical research in 1960 accounted for approximately one-quarter of federal non-defense R&D. Today it accounts for approximately half. Meanwhile, research support for most areas of the physical sciences and engineering has fallen sharply in real terms since the early 1990s. For example, federal spending on research in the life sciences increased by 28 percent between 1993 to 1999. Federal support of mathematics and computer science also increased by 45 percent over the same period, while spending on the physical sciences was 17 percent less than in 1993. Federal funding of engineering research

29  

President’s Information Technology Advisory Committee, Information Technology Research: Investing in Our Future, February 24, 1999, http://www.ccic.gov/ac/report/. The report recommends increasing the funding base for information technology research by $1.37 billion per year by fiscal year 2004, p. 3.

Suggested Citation:"III. Findings and Recommendations." National Research Council. 2001. Capitalizing on New Needs and New Opportunities: Government-Industry Partnerships in Biotechnology and Information Technologies. Washington, DC: The National Academies Press. doi: 10.17226/10281.
×

was 2 percent more in 1999 than in 1993, but chemical, electrical, and mechanical engineering research support fell more than 25 percent.30

It is wise, indeed necessary, to invest in a broad portfolio of research, because it is impossible to predict where breakthroughs will come, or how advances in one field will benefit another.31 Research is also becoming more multidisciplinary. The declines in government resources for the physical sciences and certain fields of engineering run counter to continued progress in these fields and to the broader goal of effective multidisciplinary research; they also run counter to the immediate needs of biomedicine.

The development of new medicines is one of the most prominent products of medical research. The development of new medical techniques and new drugs relies heavily on contributions from a variety of sciences. The traditional method of random prospecting for a few promising chemicals has largely been replaced by methods based on molecular structures, computer-based images, and chemical theory. Similarly, synthesis of promising compounds relies on new chemical methods able to generate pure preparations in a single molecule or collections of subtle variants.32 The exploitation of these new possibilities requires the contributions of many disciplines such as mathematics, physics, and chemistry. In short, advances in health depend on a broad range of disciplines, not just the biomedical sciences.

A case in point might be the enormous progress seen in medical diagnostics in the past two decades. Medical diagnostics now rely on imaging technologies such as ultrasound, positron-emission tomography, and computer-assisted tomography. Magnetic resonance imaging, for example, considered by many to be one of the great advances in diagnosis, is the product of atomic, nuclear and high-energy physics, quantum chemistry, computer science, cryogenics, solid state physics, and applied medicine.33

VIII. Priority Setting or Random Disinvestment? For the most part, the shifts in federal research spending shown in Figure 1 have not been the result of a conscious national debate on priorities.34 The R&D budgets of most agencies were cut in real terms in the 1993–1997 period in response to

30  

See Michael McGeary, “Recent Trends in Federal Funding of Research and Development Related to Health and Information Technology,” in this volume.

31  

Gordon Moore, in his concluding remarks—reported in the Proceedings, Part V of this volume—characterizes science as an “interconnected whole” in which advances depend on progress in all scientific and technical disciplines.

32  

Harold Varmus, “Squeeze on Science,” Washington Post, October 4, 2000, p. A33.

33  

Ibid.

34  

One presenter at the conference wondered if the shifts in research funding constituted “random disinvestments,” unintended but nonetheless injurious to national progress in R&D. See William Bonvillian, “Trends in Federal Research” in this volume. In addition, the biomedical community (scientific societies, patient advocacy groups, industry, et al.) is better organized and more effective

Suggested Citation:"III. Findings and Recommendations." National Research Council. 2001. Capitalizing on New Needs and New Opportunities: Government-Industry Partnerships in Biotechnology and Information Technologies. Washington, DC: The National Academies Press. doi: 10.17226/10281.
×

FIGURE 1 Changes in federal obligations for all performers and university/college performers, FY 1993–1999 (constant dollars).

Suggested Citation:"III. Findings and Recommendations." National Research Council. 2001. Capitalizing on New Needs and New Opportunities: Government-Industry Partnerships in Biotechnology and Information Technologies. Washington, DC: The National Academies Press. doi: 10.17226/10281.
×

the end of the Cold War and the national priorities in federal deficit reduction. The agencies cut research programs selectively. For example, DOD, the agency with the steepest cuts in R&D (more than 25 percent), increased funding of oceanographic research and held funding of research in computer science constant. Yet, it cut research investments in other fields, often substantially.35 However, the net impact on the overall pattern of federal investment in research was not planned.

Agencies such as DOD and DOE reduced R&D expenditure in response to overall post-Cold War reductions. As they provided the majority of support for certain disciplines—electrical, mechanical, and materials engineering and computer science in the case of DOD, and physics in the case of DOE—changes in their priority-setting contributed to a national-level shift in federal funding from the physical sciences and engineering to the life sciences and computer science.

Indeed, shifts in agency disbursement priorities were not the result of considered government-wide reviews, either by the Executive Branch or by Congress.36 Declining support for the physical sciences and fundamental engineering worries many observers, including many in biomedicine who know how important chemistry, physics, and mathematics have been to recent advances in molecular biology and genomics.37 Central advances in health and communications necessarily depend on more than increased funding for biomedical research and computer science in themselves.

   

in making the political case for increased funding than their counterparts in the physical sciences. See Leon Rosenberg, op. cit., in this volume on the biomedical community’s ability to make their case to policymakers. Bonvillian, op. cit., makes a similar point.

35  

DOD cuts in physics and chemistry were 63 and 27 percent, respectively. Funding of electrical, chemical, mechanical, civil, and materials engineering was reduced by 40, 60, 52, 44, and 28 percent, respectively. See Michael McGeary and Stephen A.Merrill, “Recent Trends in Federal Spending on Scientific and Engineering Research: Impacts on Research Fields and Graduate Training,” Appendix A in STEP, Securing America’s Industrial Strength. Washington, D.C.: National Academy Press, 1999.

36  

Such a government-wide review has been recommended by various groups examining federal R&D priorities. See, for example, NAS [Press Committee], Allocating Federal Funds for Science and Technology. Washington, D.C.: National Academy Press, 1995, and most recently, United States Commission on National Security/21st Century [Rudman-Hart Commission], Road Map for National Security: Imperative for Change, March 15, 2001.

37  

See Harold Varmus, “The Impact of Physics on Biology and Medicine.” Plenary Talk, Centennial Meeting of the American Physical Society, Atlanta, March 22, 1999. At: www.mskcc.org/medicalprofessionals/presidentspages/speches/theimpactofphysicsonbiologyandmedicine,html.

Suggested Citation:"III. Findings and Recommendations." National Research Council. 2001. Capitalizing on New Needs and New Opportunities: Government-Industry Partnerships in Biotechnology and Information Technologies. Washington, DC: The National Academies Press. doi: 10.17226/10281.
×

Recommendations

The recommendations that follow are based on the Committee’s commissioned research, the presentation statements and suggestions made at the conference, and the Committee’s considerable experience and deliberations in assessing government-industry partnerships.

I. Government and industry should expand support of research partnerships and other collaborative arrangements within and among sectors (government, industry, university, and nonprofit) and take other steps to facilitate multidisciplinary research leading to advances in biotechnology and information technology.

  1. Support partnerships to exploit the genome. As a first step, the Steering Committee strongly recommends that NIH and other federal agencies work with industry and university experts to identify what technical steps are needed to ensure that the United States can fully exploit the nation’s investment in the development of genomic information. For example, what kind of computing power, what advances in software, what new analytical tools (such as DNA-analyzing computing chips), and what improvements in structural biology will the U.S. need? And what research agendas in science and engineering follow from these findings? What are the “grand challenges,” the most important complex problems, that arise in these fields? Several existing analyses provide good models for preparing these new roadmaps, including the semiconductor industry’s technology roadmaps and

Suggested Citation:"III. Findings and Recommendations." National Research Council. 2001. Capitalizing on New Needs and New Opportunities: Government-Industry Partnerships in Biotechnology and Information Technologies. Washington, DC: The National Academies Press. doi: 10.17226/10281.
×

those prepared by several industries in partnership with the Energy Department’s Office of Industrial Technology.38

  1. Increase government and industry support for university research in microelectronics and related disciplines. The semiconductor industry has maintained, and even accelerated Moore’s Law.39 This has led to a proliferation of computing power throughout the economy, resulting in increased productivity and economic growth.40 To maintain Moore’s Law, significant increases in funding for physical sciences and engineering—including material sciences, chemistry, physics, and electrical engineering—are needed to build greater understanding of properties of nanostructures underpinning tomorrow’s information industries as well to capitalize on advances in biotechnology.41

  2. Address unresolved questions about research partnerships. Government-university-industry research partnerships have been very productive in both the computing and biotechnology fields. However, as Congressman Boehlert pointed out at the conference, we now face several important questions regarding partnerships.42 For example, do current partnerships help companies draw upon federally funded university basic research, or are partnerships today increasingly pulling universities away from basic research and towards applied projects of interest to established companies and to startups? How are the new intellectual property rules altering

38  

See www.semichips.org for the semiconductor industry roadmap. See also www.oit.doe.gov/industries.html for information on the Department of Energy efforts.

39  

See Gordon E.Moore, “Cramming more components onto integrated circuits,” Electronics: 38(8) April 19, 1965. Here, Dr. Moore notes that “[t]he complexity for minimum component costs has increased at a rate of roughly a factor of two per year. Certainly over the short term, this rate can be expected to continue, if not to increase. Over the longer term, the rate of increase is a bit more uncertain, although there is no reason to believe it will not remain nearly constant for at least 10 years. That means by 1975, the number of components per integrated circuit for minimum cost will be 65,000.” See also, Gordon E.Moore, “The Continuing Silicon Technology Evolution Inside the PC Platform,” Intel Developer Update, Issue 2, October 15, 1997, where he notes that he “first observed the “doubling of transistor density on a manufactured die every year” in 1965, just four years after the first planar integrated circuit was discovered. The press called this “Moore’s Law” and the name has stuck. To be honest, I did not expect this law to still be true some 30 years later, but I am now confident that it will be true for another 20 years.”

40  

See Dale Jorgenson and Kevin Stiroh, “Raising the Speed Limit: U.S. Economic Growth in the Information Age,” Brookings Papers on Economic Activity 0(1), 2000. Also see National Research Council, Measuring and Sustaining the New Economy, Washington, D.C.: National Academy Press, forthcoming.

41  

See Wesley M.Cohen and John Walsh, “Public Research, Patents, and Implications for Industrial R&D in the Drug, Biotechnology, Semiconductor, and Computer Industries,” in this volume. Also in this volume, see Kenneth Flamm, “The Federal Partnership with U.S. Industry in U.S. Computer Research: History and Current Concern.”

42  

See Congressman Sherwood Boehlert, “Opening Remarks” this volume.

Suggested Citation:"III. Findings and Recommendations." National Research Council. 2001. Capitalizing on New Needs and New Opportunities: Government-Industry Partnerships in Biotechnology and Information Technologies. Washington, DC: The National Academies Press. doi: 10.17226/10281.
×

relations between universities and companies and within universities? What is the impact of these new partnerships on education within universities? These are important questions, and both Congress and the Executive Branch might encourage further research on these topics.

  1. Support mechanisms for conducting multidisciplinary research. Government agencies and the research community also urgently need better information on what types of research arrangements can best support and perform the new type of multidisciplinary research essential to progress in biotechnology, computing, and other “complex fields.”43 Federal support through NSF and other concerned agencies, e.g., DARPA, should encourage and support innovative university-industry-government research partnerships to address emerging problems and reduce gaps in current U.S. educational capabilities. There are promising models that can and should be evaluated. Federal laboratories, for example, have long experience with multidisciplinary teams addressing complex research problems.44 Within academia, new models, such as those being pursued by the University of California at Berkeley, seem promising.45 For example, several universities are building new centers that will physically co-locate researchers from many disciplines to work together on common problems in areas such as genomics. Important questions remain, however, such as:

  • How best to train people in interdisciplinary fields such as bioinformatics;

  • How generally to get researchers in science and engineering to work together effectively;

  • How best to involve industry researchers in these university projects;

  • How federal agencies can work together to support research in fields such as bioinformatics that cut across their traditional boundaries.

43  

See Marvin Cassman, “Exploiting the Biotechnology Revolution: Training and Tools” in this volume.

44  

In this volume, see Jane Alexander “Biofutures for Multiple Missions” and Paul Horn “Meeting Needs: Realizing the Opportunities.”

45  

The Berkeley School of Public Health undertook an extensive reorganization in the fall of 1999 in order to promote these kinds of activities, including the launch a $500 million research initiative linking biological and physical sciences and engineering to spur biomedical advances. UC Berkeley plans to involve as many as 400 researchers—in fields as diverse as public health, psychology, physics, chemistry, engineering, mathematics, and computer science—in multidisciplinary research. Also involved in this effort are scientists at the Lawrence Berkeley National Laboratory. [UC Berkeley News Release 10/6/99—Public Affairs (510) 642–3734]. In this volume, see Ed Penhoet “The View from the Biotechnology Industry,” for a description.

Suggested Citation:"III. Findings and Recommendations." National Research Council. 2001. Capitalizing on New Needs and New Opportunities: Government-Industry Partnerships in Biotechnology and Information Technologies. Washington, DC: The National Academies Press. doi: 10.17226/10281.
×

Federal agencies, scientific and technical societies, and industry associations all have a stake in developing good answers to such questions.

  1. Develop public-private technology roadmaps. Federal agencies should be encouraged to work with industry associations and the scientific and engineering communities to develop technology roadmaps in important interdisciplinary fields such as genomics and bioinformatics, nanotechnology, and advanced information technology, including optoelectronics. The country needs to know what major technical barriers exist and what types of research are thus needed in order to ensure continued progress, and what investments in scientific and engineering research will be required.46

II. The scientific community, U.S. industry, and the federal government should explicitly examine the implications of recent shifts in the allocation of federal investment among fields, especially the decline in federal funding for non-defense fundamental research in the physical sciences and engineering, and address possible solutions.

  1. Conduct a comprehensive review of the federal research portfolio. Given that future progress in complex fields (such as genomics and next-generation electronics) will depend increasingly on whether the United States is strong in a wide range of scientific and engineering disciplines, the Administration should commission a comprehensive review of how post-Cold War budget trends have affected U.S. research capabilities and personnel in key areas of science and engineering. In the post-Cold War and budget-constrained environment of the early and mid-nineties, many agencies cut or increased their research budgets for mission-related reasons. Those decisions, made independently by each R&D agency in line with its particular priorities, have had major impacts on the nation’s overall research capabilities in science and engineering. The Administration could conduct this review internally, either through the appropriate White House coordinating councils, or by contracting with an outside group. In either case, the review should actively solicit analyses and documentation from experts in science and engineering, from U.S. industry, and from government experts. The review must include a review of needs in engineering research as well as scientific research, given the importance of new engineering work in providing the instruments, analytic tools, software, and other new technologies

46  

In some cases, existing programs, such as ATP, may prove to be a means of leveraging public-private resources to bring new technologies forward to the market. See the statement by Jeffrey Schloss, “Mission Synergies” in National Research Council, The Advanced Technology Program: Challenges and Opportunities, Washington, D.C.: National Academy Press, 1999, pages 56–59.

Suggested Citation:"III. Findings and Recommendations." National Research Council. 2001. Capitalizing on New Needs and New Opportunities: Government-Industry Partnerships in Biotechnology and Information Technologies. Washington, DC: The National Academies Press. doi: 10.17226/10281.
×

essential to progress in fields such as genomics, nanotechnology, and computing.

  1. Establish an “alert system.” The nation would benefit from an “alert system” that would notify government when important disciplines are getting below critical mass.47 “Benchmarking” projects now underway at, for example, the National Research Council is a possible start in this direction.48

  2. Make the case for increased support. If scientific and engineering societies and industry believe the federal government should increase funding for the physical sciences and engineering, they will need to make a strong case to the public and Congress for why such increases are in the nation’s interest.

III. Federal policymakers should support an infrastructure and create an environment conducive to research partnerships and other collaborative arrangements.49

  1. Build interdisciplinary competence for multidisciplinary research. Federal agencies can readily undertake some steps that would help build the interdisciplinary competence of researchers in fields such as bioinformatics.50

47  

Bonvillian, op. cit, describes a possible “alert system.”

48  

National Research Council, Experiments in International Benchmarking of U.S. Research Fields, Committee on Science, Engineering, and Public Policy, Washington, D.C.: National Academy Press, 2000. See also Stephen A.Merrill and Michael McGeary, “Who’s Balancing the Federal Research Portfolio and How?” Science, vol. 285, September 10, 1999, pp. 1679–1680.

49  

Additional considerations relevant to facilitating multidisciplinary research, such as that required for bioinformatics would include the need for universities to be more flexible with their curriculum since it is unlikely that large numbers of students will seek to gain separate advanced degrees in two or more disciplines. Programs that allow students to develop sound interdisciplinary backgrounds will provide the knowledge base for multidisciplinary research. The need to consider the risks firms face in developing software for bioinformatics is also important. Improving data availability, quality, and interoperability can help reduce risks inherent in funding multidisciplinary research and can hence help increase the level of private sector investments. In addition, rules on intellectual property can affect the free flow and availability of scientific results. Multidisciplinary research might benefit from improved patenting rules and policies as to what constitutes an allowable patent.

50  

The FY 2002 President’s Budget request provides funds to the NIH to make high-end instrumentation available to a broad community of basic and clinical scientists, and requests $40.2 million for the National Institute of Biomedical Imaging and Bioengineering (NIBIB). This new institute is to develop new knowledge, create new technologies, and train researchers to integrate quantitative science with biomedical research. In addition, the NIH proposes to hold State-of-the-Science meetings to develop new multidisciplinary research initiatives and to recruit new investigators from bioengineering, biocomputing, and related disciplines to focus on technology development and application. See NIH Press Release for the FY 2002 President’s Budget, April 9, 2001.

Suggested Citation:"III. Findings and Recommendations." National Research Council. 2001. Capitalizing on New Needs and New Opportunities: Government-Industry Partnerships in Biotechnology and Information Technologies. Washington, DC: The National Academies Press. doi: 10.17226/10281.
×

For example, “glue grants,” which encourage researchers from different disciplines to work together on complex problems, can be a low-cost but effective way to encourage multidisciplinary research.51 Short summer courses that bring biologists and computer scientists together also would be valuable. Any resulting initiatives in bioinformatics should explicitly consider the training of bioinformatics experts as well as R&D needs and opportunities.

  1. Increase support for interdisciplinary training of graduate students. A key element of national success in new, complex areas such as bioinformatics is training adequate numbers of high-quality graduate students in these fields.52 One problem is that while financial support for graduate students is generally available in the life sciences, such support is becoming more rare in important engineering disciplines. One result is that major U.S. companies are now establishing engineering research centers overseas largely because not enough Ph.D. engineers are available now in the United States. In the future, another result could be a lack of good engineering students and faculty to work on problems such as bioinformatics and nanotechnology. NSF and industry associations should work together to gather detailed information on these issues and consider appropriate steps.

  2. Review the impact of patent decisions on technological progress. Congress and the Executive Branch also may wish to participate actively in the NRC review of the impact of recent patent decisions (PTO decisions and court decisions) on innovation in both biotechnology and information technology.53 Uncertainty concerning the scope of new patents in areas such as biotechnology research tools, as well as risks perceived as arising from the proprietary nature of such patents could become deterrents to future innovation in these industries.54

51  

Cassman, op. cit. describes “glue grants” at NIH.

52  

See Paula Stephan, op. cit., in this volume. See also, National Research Council, Bioinformatics: Converting Data to Knowledge. Washington, D.C.: National Academy Press, 2000, p. 9, for a discussion on the need for trained personnel in bioinformatics.

53  

See National Research Council, Securing America’s Industrial Strength, Washington, D.C.: National Academy Press, 1999. The STEP Board has an active intellectual property rights (IPR) agenda. Its report, cited here, notes that strengthening and extending IPRs are appropriate policies for advanced industrial economies where intellectual assets are a principal source of growth. It also recognizes the growing friction over the assertion and exercise of IPRs, noting claims that in some circumstances, such practices discourage research.

54  

In cases where research and scientific advance is necessarily multidisciplinary, policies adopted to encourage advance in one discipline area can have broader unintended effects. If, for example, proprietary ownership of fundamental biological data poses technology risks for those creating software for bioinformatics, incentives to develop needed research tools may not appear.

Suggested Citation:"III. Findings and Recommendations." National Research Council. 2001. Capitalizing on New Needs and New Opportunities: Government-Industry Partnerships in Biotechnology and Information Technologies. Washington, DC: The National Academies Press. doi: 10.17226/10281.
×

CONCLUSION

The Committee believes that if the government, in partnership with industry, universities, and nonprofit research institutes, adopts these recommendations, the nation will experience greater progress in the research that underlies innovation. This progress will occur not only in the fields of biotechnology and information technology, but in other fields as well, because of the interconnectedness of scientific knowledge. The Committee believes that, in addition to changes in the organization of research, the nation must provide greater support for research across a broad portfolio of fields and disciplines in order to capitalize effectively on existing research investments and to ensure continued benefits for future generations.

Suggested Citation:"III. Findings and Recommendations." National Research Council. 2001. Capitalizing on New Needs and New Opportunities: Government-Industry Partnerships in Biotechnology and Information Technologies. Washington, DC: The National Academies Press. doi: 10.17226/10281.
×
Page 51
Suggested Citation:"III. Findings and Recommendations." National Research Council. 2001. Capitalizing on New Needs and New Opportunities: Government-Industry Partnerships in Biotechnology and Information Technologies. Washington, DC: The National Academies Press. doi: 10.17226/10281.
×
Page 52
Suggested Citation:"III. Findings and Recommendations." National Research Council. 2001. Capitalizing on New Needs and New Opportunities: Government-Industry Partnerships in Biotechnology and Information Technologies. Washington, DC: The National Academies Press. doi: 10.17226/10281.
×
Page 53
Suggested Citation:"III. Findings and Recommendations." National Research Council. 2001. Capitalizing on New Needs and New Opportunities: Government-Industry Partnerships in Biotechnology and Information Technologies. Washington, DC: The National Academies Press. doi: 10.17226/10281.
×
Page 54
Suggested Citation:"III. Findings and Recommendations." National Research Council. 2001. Capitalizing on New Needs and New Opportunities: Government-Industry Partnerships in Biotechnology and Information Technologies. Washington, DC: The National Academies Press. doi: 10.17226/10281.
×
Page 55
Suggested Citation:"III. Findings and Recommendations." National Research Council. 2001. Capitalizing on New Needs and New Opportunities: Government-Industry Partnerships in Biotechnology and Information Technologies. Washington, DC: The National Academies Press. doi: 10.17226/10281.
×
Page 56
Suggested Citation:"III. Findings and Recommendations." National Research Council. 2001. Capitalizing on New Needs and New Opportunities: Government-Industry Partnerships in Biotechnology and Information Technologies. Washington, DC: The National Academies Press. doi: 10.17226/10281.
×
Page 57
Suggested Citation:"III. Findings and Recommendations." National Research Council. 2001. Capitalizing on New Needs and New Opportunities: Government-Industry Partnerships in Biotechnology and Information Technologies. Washington, DC: The National Academies Press. doi: 10.17226/10281.
×
Page 58
Suggested Citation:"III. Findings and Recommendations." National Research Council. 2001. Capitalizing on New Needs and New Opportunities: Government-Industry Partnerships in Biotechnology and Information Technologies. Washington, DC: The National Academies Press. doi: 10.17226/10281.
×
Page 59
Suggested Citation:"III. Findings and Recommendations." National Research Council. 2001. Capitalizing on New Needs and New Opportunities: Government-Industry Partnerships in Biotechnology and Information Technologies. Washington, DC: The National Academies Press. doi: 10.17226/10281.
×
Page 60
Suggested Citation:"III. Findings and Recommendations." National Research Council. 2001. Capitalizing on New Needs and New Opportunities: Government-Industry Partnerships in Biotechnology and Information Technologies. Washington, DC: The National Academies Press. doi: 10.17226/10281.
×
Page 61
Suggested Citation:"III. Findings and Recommendations." National Research Council. 2001. Capitalizing on New Needs and New Opportunities: Government-Industry Partnerships in Biotechnology and Information Technologies. Washington, DC: The National Academies Press. doi: 10.17226/10281.
×
Page 62
Suggested Citation:"III. Findings and Recommendations." National Research Council. 2001. Capitalizing on New Needs and New Opportunities: Government-Industry Partnerships in Biotechnology and Information Technologies. Washington, DC: The National Academies Press. doi: 10.17226/10281.
×
Page 63
Suggested Citation:"III. Findings and Recommendations." National Research Council. 2001. Capitalizing on New Needs and New Opportunities: Government-Industry Partnerships in Biotechnology and Information Technologies. Washington, DC: The National Academies Press. doi: 10.17226/10281.
×
Page 64
Suggested Citation:"III. Findings and Recommendations." National Research Council. 2001. Capitalizing on New Needs and New Opportunities: Government-Industry Partnerships in Biotechnology and Information Technologies. Washington, DC: The National Academies Press. doi: 10.17226/10281.
×
Page 65
Suggested Citation:"III. Findings and Recommendations." National Research Council. 2001. Capitalizing on New Needs and New Opportunities: Government-Industry Partnerships in Biotechnology and Information Technologies. Washington, DC: The National Academies Press. doi: 10.17226/10281.
×
Page 66
Suggested Citation:"III. Findings and Recommendations." National Research Council. 2001. Capitalizing on New Needs and New Opportunities: Government-Industry Partnerships in Biotechnology and Information Technologies. Washington, DC: The National Academies Press. doi: 10.17226/10281.
×
Page 67
Suggested Citation:"III. Findings and Recommendations." National Research Council. 2001. Capitalizing on New Needs and New Opportunities: Government-Industry Partnerships in Biotechnology and Information Technologies. Washington, DC: The National Academies Press. doi: 10.17226/10281.
×
Page 68
Suggested Citation:"III. Findings and Recommendations." National Research Council. 2001. Capitalizing on New Needs and New Opportunities: Government-Industry Partnerships in Biotechnology and Information Technologies. Washington, DC: The National Academies Press. doi: 10.17226/10281.
×
Page 69
Suggested Citation:"III. Findings and Recommendations." National Research Council. 2001. Capitalizing on New Needs and New Opportunities: Government-Industry Partnerships in Biotechnology and Information Technologies. Washington, DC: The National Academies Press. doi: 10.17226/10281.
×
Page 70
Next: IV. Proceedings »
Capitalizing on New Needs and New Opportunities: Government-Industry Partnerships in Biotechnology and Information Technologies Get This Book
×
Buy Paperback | $85.00 Buy Ebook | $69.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

This report addresses a topic of recognized policy concern. To capture the benefits of substantial U.S. investments in biomedical R&D, parallel investments in a wide range of seemingly unrelated disciplines are also required. This report summarizes a major conference that reviewed our nation's R&D support for biotechnology and information technologies. The volume includes newly commissioned research and makes recommendations and findings concerning the important relationship between information technologies and biotechnology. It emphasizes the fall off in R&D investments needed to sustain the growth of the U.S. economy and to capitalize on the growing investment in biomedicine. It also encourages greater support for inter-disciplinary training to support new areas such as bioinformatics and urges more emphasis on and support for multi-disciplinary research centers.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!